Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Rgenta Therapeutics launches with $20 million to develop small molecules that target RNA

by Ryan Cross
April 10, 2020 | A version of this story appeared in Volume 98, Issue 14

 

Rgenta Therapeutics, a start-up with plans to develop small-molecule drugs that target RNA, has raised a $20 million seed investment, co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China. The company is focused on drugging RNA regulation and splicing to treat cancer and neurological diseases. The company is based on work by scientific cofounder Zhiping Weng, who studies DNA and RNA regulation at the University of Massachusetts Medical School.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.